Bundestag Keeps Drug Price Freeze in place

In contrast to speculation only days earlier, Germany's national parliament, the Bundestag, on 19 December passed pharmaceuticals legislation extending the mandatory discount awarded by pharmaceutical producers to public health insurers until the end of March 2014.

In the interim, the parliamentary action keeps the rebate from slipping to 7% from currently 16% and also prevents the expiration of a price freeze on patented drugs in place since 2010.

During 2014, the grand coalition of chancellor Angela Merkel's Christian Democrats and the Social Democrats will introduce new legislation dropping the rebate back to 7% but keeping a moratorium on drug price increases until the end of 2017. The price rebate was raised to 16% in 2010 to help stabilize the finances of public health insurance companies

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.